Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26726779 | 0.80 | KDM4E (0.42) | ALDH1A1CYP1A2KMT2AGAAADORA3 | |
| SCHEMBL19284286 | 0.78 | KMT2A (0.38) | MAPTALDH1A1CYP1A2KMT2AGAA | |
| SCHEMBL13118705 | 0.77 | CYP1A2 (0.42) | MAPTALDH1A1CYP1A2KMT2AGAA | |
| SCHEMBL5848830 | 0.75 | CYP1A2 (0.41) | MAPTALDH1A1CYP1A2KMT2AGAA | |
| SCHEMBL3549149 | 0.74 | CYP1A2 (0.40) | MAPTCYP1A2KMT2AGAAADORA3 | |
| SCHEMBL3548683 | 0.73 | NPC1 (0.39) | ALDH1A1CYP1A2KMT2AGAAADORA3 | |
| SCHEMBL23645428 | 0.72 | RAB9A (0.41) | ALDH1A1CYP1A2KMT2AGAAKDM4E | |
| SCHEMBL31389518 | 0.71 | NPC1 (0.40) | CYP1A2KMT2AGAAADORA3KDM4E | |
| SCHEMBL23645415 | 0.71 | KMT2A (0.38) | MAPTALDH1A1CYP1A2KMT2AGAA | |
| SCHEMBL31389427 | 0.71 | CYP1A2 (0.37) | MAPTALDH1A1CYP1A2KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421225-B2 | Heteroaromatic amide derivative and medicament containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2025-09-23 | — | — | US | disclosed |
| CN-112689636-B | Novel heteroatom aromatic amide derivative and pharmaceutical agent containing same | 科研制药株式会社 | 2024-08-20 | — | — | CN | disclosed |
| CN-118434744-A | Nitrogen-containing macrocyclic compound, and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2024-08-02 | — | — | CN | disclosed |
| EP-3851436-B1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2024-06-12 | — | — | EP | disclosed |
| US-20230086366-A1 | Novel heteroaromatic amide derivative and medicament containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2023-03-23 | — | — | US | disclosed |
| EP-3851436-A1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2021-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086366-A1 | Novel heteroaromatic amide derivative and medicament containing the same | SCN7A, HCN4, SCN4A | MAPT 4617/4885ALDH1A1 1627/4885CYP1A2 458/4885 |
| US-12421225-B2 | Heteroaromatic amide derivative and medicament containing the same | SCN7A, HCN4, SCN4A | MAPT 4572/4885ALDH1A1 1596/4885CYP1A2 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.